Preparation and in vitro/in vivo evaluation of mucosal adjuvant in situ forming gels with diphtheria toxoid

References

• Aggerbeck H, Gizurarson S, Heon I, Wantzin J. (1997). Intranasal booster vaccination against diphtheria and tetanus in man. Vaccine 15:307–16
   PubMed Web of Science ®Google Scholar
• Aguilar JC, Rodriguez EG. (2007). Vaccine adjuvants revisited. Vaccine 25:3752–62
   PubMed Web of Science ®Google Scholar
• Alpar HO, Atuah KN, Bramwell VW, Somavarapu S. (2005). Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 57:411–30
   PubMed Web of Science ®Google Scholar
• Amidi M, Borchard G, Hennink WE, et al. (2006). Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Rel 111:107–16
   PubMed Web of Science ®Google Scholar
• Andrews GP, Jones DS, Laverty TP. (2009). Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharmaceut Biopharmaceut 71:505–18
   PubMed Web of Science ®Google Scholar
• Arora P, Garg S, Sharma S. (2002). Permeability issues in nasal drug delivery. Drug Discov Today 7:967–75
   PubMed Web of Science ®Google Scholar
• Barichello JM, Morishita M, Nagai T, Takayama K. (1999). Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats. Int J Pharmaceut 184:189–98
   PubMed Web of Science ®Google Scholar
• Bellamy R. (2005). Freedman A. Immun Med 33:17–21
   Google Scholar
• Bertram U, Bodmeier R. (2006). In situ gelling, bioadhesive nasal inserts for extended drug delivery: ın vitro characterization of a new nasal dosage form. Eur J Pharmaceut Sci 27:62–71
   PubMed Web of Science ®Google Scholar
• Bilensoy E, Hincal AA, Rouf MA, et al. (2006). Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole: β-cyclodextrin complex. AAPS Pharm Sci Tech 7:E1–7
   PubMed Web of Science ®Google Scholar
• Choi HG, Jung JH, Kim CK, et al. (1998). Development of in situ-gelling and mucoadhesive acetaminophen liquid suppository. Int J Pharmaceut 165:33–44
   Web of Science ®Google Scholar
• Coeshott CM, Blonder JM, Rosenthal GJ, et al. (2004). Pluronic® F127-based systemic vaccine delivery systems. Vaccine 22:2396–405
   PubMed Web of Science ®Google Scholar
• Davis SS. (2001). Nasal vaccines. Adv Drug Deliv Rev 51:21–42
   PubMed Web of Science ®Google Scholar
• Davis SS. (2006). The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine 24:7–10
   Web of Science ®Google Scholar
• De Magistris MT. (2006). Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 58:52–67
   PubMed Web of Science ®Google Scholar
• Devrim B, Bozkir A, Canefe K. (2007). Preparation and evaluation of surface-modified PLGA microparticles with chitosan for pulmonary delivery of proteins. Adv Chitin Sci 10:349–54
   Google Scholar
• European Pharmacopoeia Online. (2009). Monographs: Aassay of diphtheria vaccine (adsorbed). 217–22
   Google Scholar
• Han IK, Cho HJ, Jung WW, et al. (2006). Thermosensitive and mucoadhesive delivery systems of mucosal vaccines. Methods 38:106–11
   PubMed Web of Science ®Google Scholar
• Illum L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharmaceut Res 15:1326–31
   PubMed Web of Science ®Google Scholar
• Illum L, Davis SS. (2001). Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future. Adv Drug Deliv Rev 51:1–3
   PubMed Web of Science ®Google Scholar
• Illum L, Davis SS, Fisher AN, et al. (2001). Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51:81–96
   PubMed Web of Science ®Google Scholar
• Jung T, Breitenbach A, Hungerer K, et al. (2001). Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharmaceut Res 18:352–60
   PubMed Web of Science ®Google Scholar
• Kang ML, Cho CS, Guo DD, et al. (2007). Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine 25:4602–10
   PubMed Web of Science ®Google Scholar
• Keck T, Leiacker R, Riechelmann H, Rettinger G. (2000). Temperature profile in the nasal cavity. Laryngoscope 110:651–4
   PubMed Web of Science ®Google Scholar
• Kotze AF, de Boer AG, Junginger HE, et al. (1998). Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. Eur J Pharmaceutl Sci 7:145–51
   Web of Science ®Google Scholar
• Lin HR, Sung KC. (2000). Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Rel 69:379–88
   PubMed Web of Science ®Google Scholar
• Matschke C, Fahr A, Isele U, van Hoogevest P. (2002). Sustained-release injectables formed in situ and their potential use for veterinary products. J Control Rel 85:1–15
   PubMed Web of Science ®Google Scholar
• Matthias DM, Garrison MM, Nelson C, et al. (2007). Freezing temperatures in the vaccine cold chain: A systematic literature review. Vaccine 25:3980–6
   PubMed Web of Science ®Google Scholar
• McNeela EA, Davis SS, Illum L, et al. (2001). A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19:1188–98
   Web of Science ®Google Scholar
• Nagler-Anderson C. (2001). Man the barrier! Strategic defences in the intestinal mucosa. Nature Rev Immunol 18:59–67
   Google Scholar
• Nanjawade BK, Manjappa AS, Manvi FV. (2007). In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Rel 122:119–34
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. (2006). Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6:148–58
   PubMed Web of Science ®Google Scholar
• O’Hagan DT. (1998). Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev 34:305–20
   PubMed Web of Science ®Google Scholar
• Park JS, Kim CK, Kim JM, et al. (2001). In situ gelling and mucoadhesive polymer vehicles for controlled intranasal delivery of plasmid DNA. J Biomed Mater Res 59:144–51
   Web of Science ®Google Scholar
• Saatçi F, Bozkır A. (2003). Aşıların nazal yoldan uygulanışı. J Fac Pharm 32:175–93
   Google Scholar
• Saettone MF, Burgalassi S, Chetoni P, et al. (1989). Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. Int J Pharmaceut 51:203–12
   Web of Science ®Google Scholar
• Saka OM, Bozkir A. (2012). Formulation and in vitro characterization of PEGylated chitosan and polyethylene imine polymers with thrombospondin-I gene bearing pDNA. J Biomed Mater Res – Part B Appl Biomater 100B:984–92
   Web of Science ®Google Scholar
• Sharma S, Benson HAE, Chen Y, Mukkur TKS. (2009). Pharmaceutical aspects of ıntranasal delivery of vaccines using particulate systems. J Pharmaceut Sci 98:812–43
   PubMed Web of Science ®Google Scholar
• Soane RJ, Davis SS, Jones NS, et al. (1999). Evaluation of the clearance characteristics of bioadhesive. Int J Pharmaceut 178:55–65
   PubMed Web of Science ®Google Scholar
• Srividya B, Amin PD, Cardoza RM. (2001). Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Rel 73:205–11
   PubMed Web of Science ®Google Scholar
• Talasaz AHH, Atyabi F, Dinarvand R, et al. (2008). In situ gel forming systems of poloxamer 407 and hydroxypropyl cellulose or hydroxypropyl methyl cellulose mixtures for controlled delivery of vancomycin. J Appl Polym Sci 109:2369–74
   Web of Science ®Google Scholar
• Vila A, Alonso MJ, Behrens I, et al. (2004). Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharmaceut Biopharmaceut 57:123–31
   PubMed Web of Science ®Google Scholar
• Zaki NM, Abd Elhadyb SS, Awada GA, Mortadaa ND. (2007). Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharmaceut Sci 32:296–307
   PubMed Web of Science ®Google Scholar